Cargando…

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074

Knowledge of intracellular pharmacokinetics of anticancer agents is imperative for understanding drug efficacy as well as intrinsic and acquired cellular resistance mechanisms. However, the factors driving subcellular drug distribution are complex and poorly understood. Here, we describe for the fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Englinger, Bernhard, Kallus, Sebastian, Senkiv, Julia, Laemmerer, Anna, Moser, Patrick, Gabler, Lisa, Groza, Diana, Kowol, Christian R., Heffeter, Petra, Grusch, Michael, Berger, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315953/ https://www.ncbi.nlm.nih.gov/pubmed/30544798 http://dx.doi.org/10.3390/cells7120259

Ejemplares similares

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
por: Englinger, Bernhard, et al.
Publicado: (2017)

Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
por: Englinger, Bernhard, et al.
Publicado: (2020)

PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1
por: Nguyen, P T, et al.
Publicado: (2013)

Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma
por: Balasubramanian, Brinda, et al.
Publicado: (2023)

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression
por: Englinger, Bernhard, et al.
Publicado: (2016)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Development of a cobalt(iii)-based ponatinib prodrug system
por: Mathuber, Marlene, et al.
Publicado: (2021)

TC-1 Overexpression Promotes Cell Proliferation in Human Non-Small Cell Lung Cancer that Can Be Inhibited by PD173074
por: Lei, Jie, et al.
Publicado: (2014)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 in apo state and in complex with inhibitor PD173074
por: Sanfelice, Domenico, et al.
Publicado: (2018)

PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells
por: Qiao, Chuchu, et al.
Publicado: (2020)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
por: Ruzickova, Eliska, et al.
Publicado: (2019)

Influence of lysosomal sequestration on multidrug resistance in cancer cells
por: Halaby, Reginald
Publicado: (2019)

Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
por: Zhitomirsky, Benny, et al.
Publicado: (2014)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance
por: Englinger, B, et al.
Publicado: (2017)

Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid
por: Yousef, Malaz, et al.
Publicado: (2022)

Correction: Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
por: Zhitomirsky, Benny, et al.
Publicado: (2022)

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling
por: Miklos, Walter, et al.
Publicado: (2016)

The thiosemicarbazone Me(2)NNMe(2) induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition
por: Hager, Sonja, et al.
Publicado: (2018)

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones
por: Heffeter, Petra, et al.
Publicado: (2012)

TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer
por: Zhao, Ben, et al.
Publicado: (2020)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets
por: Kirchhofer, Dominik, et al.
Publicado: (2022)

Lysosomal Fusion: An Efficient Mechanism Increasing Their Sequestration Capacity for Weak Base Drugs without Apparent Lysosomal Biogenesis
por: Skoupa, Nikola, et al.
Publicado: (2020)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
por: Heffeter, Petra, et al.
Publicado: (2013)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells
por: Wiggins, Helen L., et al.
Publicado: (2015)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness
por: Gabler, Lisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aukatq3okps6sihhrj41li6oom